Pharmacokinetic and pharmacodynamic evaluation of sulbactam‐durlobactam in a critically ill patient on continuous venovenous hemofiltration infected with carbapenem‐resistant Acinetobacter baumannii‐calcoaceticus complex
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · 2025
DOI: 10.1002/phar.70027 ↗Kurz gefasst
Fallbericht in der Zeitschrift Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2025. Verfasst von Wesley D Kufel und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy Practice, State University of New York at Binghamton School of Pharmacy and Pharmaceutical Sciences, Binghamton, New York, USA. Hauptthemen laut MEDLINE: Sulbactam, Acinetobacter baumannii, Acinetobacter Infections, Anti-Bacterial Agents. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Innoviva Specialty Therapeutics.
Abstract (Originalsprache)
Background
Drug databases currently do not provide dosing guidance for sulbactam‐durlobactam in continuous renal replacement therapy. Herein, we present the first in vivo pharmacokinetic (PK) evaluation of sulbactam‐durlobactam during continuous venovenous hemofiltration (CVVH) in a patient with carbapenem‐resistant Acinetobacter baumannii‐calcoaceticus complex (CRAB) bacteremia and ventilator‐associated bacterial pneumonia (VABP).
Methods
A 59‐year‐old critically ill patient (body mass index 60 kg/m 2 ) required CVVH and developed CRAB bacteremia secondary to VABP. Sulbactam‐durlobactam 2 g every 4 h infused over 3 h was initiated based on previous ex vivo data and the effluent rate of 6 L/h. The sulbactam‐durlobactam minimum inhibitory concentration (MIC) was determined by reference broth microdilution, and whole genome sequencing (WGS) was performed. Steady‐state pre‐filter blood, post‐filter blood, and effluent samples were collected on three different dosing intervals to characterize plasma exposure and estimate the sieving coefficient (SC).
Results
The sulbactam‐durlobactam MIC was 4/4 mcg/mL (susceptible). WGS revealed penicillin‐binding protein (PBP)‐1b and PBP‐3 mutations. The selected dose exceeded sulbactam and durlobactam PK/pharmacodynamic (PD) targets with 100% free time above MIC ( f T > MIC) and the ratio of area under the unbound concentration‐time curve to MIC ( f AUC/MIC) = 139, respectively. The SC for sulbactam and durlobactam was 0.68 and 0.67, respectively, and protein binding was 54% and 51%, respectively. Sulbactam‐durlobactam monotherapy resulted in initial microbiological clearance for CRAB bacteremia but recurred later in hospitalization 11 days after sulbactam‐durlobactam treatment. The patient was ultimately transitioned to comfort care.
Conclusion
Sulbactam‐durlobactam monotherapy dosed at 2 g every 4 h (3‐h infusion) in CVVH achieved PD targets for this CRAB isolate with a MIC of 4/4 mcg/ml. Although sulbactam‐durlobactam monotherapy resulted in initial microbiological clearance for the CRAB bacteremia, recurrence occurred, and the patient ultimately died.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy Practice, State University of New York at Binghamton School of Pharmacy and Pharmaceutical Sciences, Binghamton, New York, USA.
- Deparment of Pharmacy, State University of New York Upstate University Hospital, Syracuse, New York, USA.
- Division of Infectious Diseases, Department of Medicine, State University of New York Upstate Medical University, Syracuse, New York, USA.
- Center for Anti-Infective Research and Development, Hartford Hospital, Hartford, Connecticut, USA.
- University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
- Department of Pharmacy, Arnot Ogden Medical Center, Elmira, New York, USA.
ORCID-Profile: Wesley D Kufel, Aliaa Fouad, Hanna F Roenfanz, Ryan K Shields, Kathleen Hanrahan, Joseph L Kuti
Förderung
- Innoviva Specialty Therapeutics
Zitieren
APA
Kufel, W. D., Zeineddine, N., Fouad, A., Roenfanz, H. F., Shields, R. K., Kline, E. G., Warner, J., Hanrahan, K., & Kuti, J. L. (2025). Pharmacokinetic and pharmacodynamic evaluation of sulbactam‐durlobactam in a critically ill patient on continuous venovenous hemofiltration infected with carbapenem‐resistant Acinetobacter baumannii‐calcoaceticus complex. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. https://doi.org/10.1002/phar.70027
Vancouver
Kufel WD, Zeineddine N, Fouad A, Roenfanz HF, Shields RK, Kline EG, et al. Pharmacokinetic and pharmacodynamic evaluation of sulbactam‐durlobactam in a critically ill patient on continuous venovenous hemofiltration infected with carbapenem‐resistant Acinetobacter baumannii‐calcoaceticus complex. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2025. doi:10.1002/phar.70027
BibTeX
@article{Kufel2025,
author = {Kufel, Wesley D and Zeineddine, Nabil and Fouad, Aliaa and Roenfanz, Hanna F and Shields, Ryan K and Kline, Ellen G and Warner, Jameson and Hanrahan, Kathleen and Kuti, Joseph L},
title = {Pharmacokinetic and pharmacodynamic evaluation of sulbactam‐durlobactam in a critically ill patient on continuous venovenous hemofiltration infected with carbapenem‐resistant Acinetobacter baumannii‐calcoaceticus complex},
journal = {Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy},
year = {2025},
doi = {10.1002/phar.70027}
}
EUVIMED